GGrantIndex
← Leaderboards

Aleem Gangjee

Wayne State University

Google Scholar ↗PubMed ↗ORCID ↗
$13,765,845
Attributed
$18,817,658
Total exposure
14
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,817,658 · 14

By mechanism

R01$18,438,158 · 13
R21$379,500 · 1

Top collaborators

Most similar at Wayne State University

Same institution · by research overlap

Others in their field

Top investigators on “Analog”

Research focus

AnalogEvaluationSeriesIn VivoToxic EffectLeadBaseCytotoxicityIn VitroBiologicalStructureTumorBinding (Molecular Function)Inhibitor/AntagonistCellsAntitumor AgentMetabolicMalignant NeoplasmsNeoplastic CellMolecularInhibitory Concentration 50Pharmaceutical PreparationsEnzymesFailure (Biologic Function)

Grant awards (54)

Therapeutic Targeting Mitochondrial C1 Metabolism$614,438
R01 · FY2025 · CA
Therapeutic Targeting Mitochondrial C1 Metabolism$583,716
R01 · FY2024 · CA
Therapeutic Targeting Mitochondrial C1 Metabolism$602,150
R01 · FY2023 · CA
Therapeutic Targeting Mitochondrial C1 Metabolism$602,150
R01 · FY2022 · CA
Therapeutic Targeting Mitochondrial C1 Metabolism$641,436
R01 · FY2021 · CA
Novel Cytoskeletal Stabilizers as Potential Treatments for Limbic Lewy Body Disorders$379,500
R21 · FY2020 · AG · contact PI
Pneumocystis jirovecii Targeted Antiopportunistic Agents$380,747
R01 · FY2016 · AI · contact PI
Purine Synthesis Inhibitors with Selective Folate Receptor Tumor Transport$558,208
R01 · FY2015 · CA · contact PI
Discovery of novel PCFT-targeted agents$458,348
R01 · FY2015 · CA
Pneumocystis jirovecii Targeted Antiopportunistic Agents$380,747
R01 · FY2015 · AI · contact PI
Water Soluble Antimitotics That Circumvent Rumor Resistance$313,702
R01 · FY2015 · CA · contact PI
Purine Synthesis Inhibitors with Selective Folate Receptor Tumor Transport$546,172
R01 · FY2014 · CA · contact PI
Discovery of novel PCFT-targeted agents$444,742
R01 · FY2014 · CA
Pneumocystis jirovecii Targeted Antiopportunistic Agents$380,747
R01 · FY2014 · AI · contact PI
Water Soluble Antimitotics That Circumvent Rumor Resistance$304,291
R01 · FY2014 · CA · contact PI
Purine Synthesis Inhibitors with Selective Folate Receptor Tumor Transport$583,778
R01 · FY2013 · CA · contact PI
Discovery of novel PCFT-targeted agents$431,131
R01 · FY2013 · CA
Pneumocystis jirovecii Targeted Antiopportunistic Agents$357,903
R01 · FY2013 · AI · contact PI
Water Soluble Antimitotics That Circumvent Rumor Resistance$294,880
R01 · FY2013 · CA · contact PI
Discovery of novel PCFT-targeted agents$458,807
R01 · FY2012 · CA
Pneumocystis jirovecii Targeted Antiopportunistic Agents$380,747
R01 · FY2012 · AI · contact PI
Water Soluble Antimitotics That Circumvent Rumor Resistance$313,298
R01 · FY2012 · CA · contact PI
Discovery of novel PCFT-targeted agents$462,299
R01 · FY2011 · CA
Water Soluble Antimitotics That Circumvent Rumor Resistance$312,731
R01 · FY2011 · CA · contact PI
Single Agents with Designed Combination Chemotherapy Potential$305,782
R01 · FY2010 · CA · contact PI
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents$253,704
R01 · FY2010 · CA · contact PI
Antitumor Antimitotics That Reverse Tumor Resistance$247,872
R01 · FY2010 · CA · contact PI
Novel, P. jirovecii Specific Antipneumocystis Agents$313,094
R01 · FY2009 · AI · contact PI
Single Agents with Designed Combination Chemotherapy Potential$305,782
R01 · FY2009 · CA · contact PI
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents$253,704
R01 · FY2009 · CA · contact PI
Antitumor Antimitotics That Reverse Tumor Resistance$247,872
R01 · FY2009 · CA · contact PI
Novel, P. jirovecii Specific Antipneumocystis Agents$313,094
R01 · FY2008 · AI · contact PI
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents$253,704
R01 · FY2008 · CA · contact PI
Antitumor Antimitotics That Reverse Tumor Resistance$247,872
R01 · FY2008 · CA · contact PI
Novel, P. jirovecii Specific Antipneumocystis Agents$319,158
R01 · FY2007 · AI · contact PI
Novel Single, Dual and Multitargeted Inhibitors of RTKs$278,580
R01 · FY2007 · CA · contact PI
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents$253,704
R01 · FY2007 · CA · contact PI
Antitumor Antimitotics That Reverse Tumor Resistance$247,872
R01 · FY2007 · CA · contact PI
Novel, P. jirovecii Specific Antipneumocystis Agents$328,426
R01 · FY2006 · AI · contact PI
Novel Single, Dual and Multitargeted Inhibitors of RTKs$286,901
R01 · FY2006 · CA · contact PI
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents$261,282
R01 · FY2006 · CA · contact PI
Antitumor Antimitotics That Reverse Tumor Resistance$255,275
R01 · FY2006 · CA · contact PI
Novel Single, Dual and Multitargeted Inhibitors of RTKs$293,806
R01 · FY2005 · CA
Novel Single, Dual and Multitargeted Inhibitors of RTKs$293,806
R01 · FY2004 · CA
NOVEL NONINDUCIBLE THYMIDYLATE SYNTHASE INHIBITORS$226,164
R01 · FY2004 · CA
Novel Single, Dual and Multitargeted Inhibitors of RTKs$293,806
R01 · FY2003 · CA
Third Generation Antiopportunistic Agents$267,541
R01 · FY2003 · AI
NOVEL NONINDUCIBLE THYMIDYLATE SYNTHASE INHIBITORS$226,164
R01 · FY2003 · CA
Third Generation Antiopportunistic Agents$236,285
R01 · FY2002 · AI
NOVEL NONINDUCIBLE THYMIDYLATE SYNTHASE INHIBITORS$226,164
R01 · FY2002 · CA
Third Generation Antiopportunistic Agents$267,541
R01 · FY2001 · AI
STRUCTURE BASED ANALOGS AS ANTIOPPORTUNISTIC AGENTS$252,999
R01 · FY2001 · AI
NOVEL NONINDUCIBLE THYMIDYLATE SYNTHASE INHIBITORS$226,164
R01 · FY2001 · CA
STRUCTURE BASED ANALOGS AS ANTIOPPORTUNISTIC AGENTS$246,872
R01 · FY2000 · AI